ALS Agent Dazucorilant Associated With Lower 2-Year Mortality in Exploratory DAZALS Analysis

Aggregator

07 Nov 2026 0 comments

Two-year data from the phase 2 DAZALS trial showed a lower risk of death with dazucorilant 300 mg/day vs placebo in ALS, although the study did not meet its functional primary end point.